M&A analysis (Accretion / Dilution) when target tech startup has negative FCF?

Hi All,

How should we go about M&A analysis (Accretion / Dilution) when the target tech startup has negative FCFF? EPS will decrease, so how to justify the txn quantitatively?
I believe it would be a standard question for people in Tech, as many highly valued targets have negative FCFF.

Appreciate the help!

11 Comments
 

I would agree this is the best approach for this, if you really wanted a model justificatoon for the deal.

The point of acquiring high growth tech companies is in its name - growth. You're not purchasing it to obtain immediate EPS / value accretion; you buy it knowing that it will potentially generate masses of earnings and cash flows in the future. A standard 1, 2 or even 5 year accretion will not showcase this benefit.

 

(1) Even if FCF was positive, it makes little sense to run accretion / dilution in an acquisition of a start-up (size too small) unless its growing at triple digits

There must have been some rationale why this start-up is acquired - use that as a starting point. With this start-up under your client’s umbrella, will you be able to grow certain product line perhaps?
 

(2) It all boils down to how much info you have.

(3) A bit puzzled how a start-up managed to get listed. Is it really a start up?

 

Surprised no one brought this up yet. If FCF is negative because of massive capex or NWC shortfalls while income statement items aren't negative, you can still have an accretive deal. That said, if capex is super high and the co is in growth mode, I'd bet operating results aren't that great either. But just saying "negative FCF" doesn't mean the numbers won't be accretive without further info. Especially if it's all-cash and therefore no share count dilution

 

Iste suscipit hic ad error autem fuga est aspernatur. Dolorem alias ut debitis ut at ut quod. Animi maxime quasi voluptatum consequatur mollitia vero error.

Tempora sequi quisquam voluptatem. Quia nobis et velit quis ratione cumque. Nesciunt iusto laudantium magnam magni cumque.

Ipsum sunt ex porro ut qui. Qui dolorum qui cupiditate et. Libero non et magni sed nisi.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”